VLDL-C Levels Research Articles

Interleukin 1β And Interleukin-6 and Some Oxidants in Patients With Stable Angina

ROS play an essential physiological roles in the cellular homoeostasis and cell signaling under normal circumstances. The overexpression of ROS was involved in the pathological events of several diseases, including cardiovascular, because they cause damage to many cell structures.This study aims to evaluate the levels of inflammatory biomarkers, [interleukin-6 (IL-6) and interleukin-1beta (IL-1β)] in stable angina patients and their relationship with oxidative stress. The current study is a case-control one performed on 88 patients with stable angina and 44 people as a control group attending the Nasiriyah Heart Center from August 2023 to March 2024. All cases were diagnosed by cardiologists and confirmed by laboratory investigations. Blood samples (10 ml) were collected from patients. Serum was isolated after centrifugation and stored at -20°C. Serum CK-MB, MYO and Trop I were determined by electro-chemiluminescence immunoassay. While, the ELISA was employed to assess the levels of human IL-6, human IL-1 β, SOD, (GSH-Px/ GPX), total cholesterol, triglycerides, LDL, VLDL and HDL, using the kits from Solarbio, China. The patients with stable angina didn’t show significant variation in the serum level of troponin I and CK-MB in comparison with control, while serum myoglobin level was significantly increased in patients with stable angina compared to control. Although the level of total cholesterol was insignificantly increased, but the levels of triglyceride (TG), VLDL-C and LDL-C were significantly increased, while the serum level of HDL-C was significantly declined in comparison with control. The serum levels IL-6 and IL-1β, in addition to activities of SOD and GPx were increased significantly in patients of angina compared to control. We could conclude that IL-1β, IL-6, SOD and GPx are increased in stable angina. Inflammatory events and oxidative stress could play an important roles in initiation of atherosclerosis and subsequent angina.

Hesperidin & Apigenin Attenuates Diabetes & Lipid Levels in Experimentally Induced Diabetes Mellitus in Wistar Rats.

The aim of the present investigation is to study the antidiabetic potential of Hesperidin and Apigenin in Diabetic rats. Wistar Albino rats of either sex (150 to 200 g) were purchased from the CPCSEA approved vendor New Delhi. A total of three animals were used, which received a single oral dose in 500 mg/kg, body weight of different flavonoids. Doses equivalent to 25 mg and 50 mg per kilogram body weight were calculated, and suspended in 1% w/v Tween 80 solutions for the experiment. For OGTT, Different doses of both flavonoids i.e. Hesperidin & Apigenin were administered 60 min prior to oral glucose load (2.0 g/kg). Diabetes was induced in overnight fasted rats by Streptozotocin (60 mg/kg), 15 min. after the i.p. administration of Nicotinamide (120mg/kg). Streptozotocin was dissolved in citrate buffer (0.1 M, pH 4.5) & nicotinamide was dissolved in normal saline. During the study period of 21 days, animals was weighed at 0, 7, 14 and 21 day and effect of vehicle, standard drug and all solvent fractions on body weight was determined. Blood samples was collected by cardiac puncture and retroorbital plexus method into EDTA sprinkled tubes and centrifuged at 3000 rpm for 20 min. Serum was separated as supernatant and stored at -20°C until analysis performed. The biochemical parameters, namely hemoglobin, urea, creatinine, total protein, total cholesterol, triglycerides, HDL determined. The other biochemical tests were performed using kits from Erba Diagnostics. Hesperidin and Apigenin significantly prevented the increase in blood glucose levels after 60 min. of glucose administration at the doses of 25 and 50 mg/kg. After 21 days blood samples were collected by retro-orbital plexus under mild anesthesia. Diabetic control group with no drug treatment showed no significant difference in the fasting serum glucose level after 21 days treatment as compared to the initial day treatment. Hesperidin & Apigenin (25 mg/kg & 50 mg/kg) treated diabetic rat showed a significant (p < 0.05) increase in body weight. The diabetic rat treated with glibenclaimide (10mg/kg) showed gradual and consistent increase in body weight. Treated diabetic rat with Hesperidin & Apigenin showed significant fall in total cholesterol, triglycerides, HDL-C, LDL-C and VLDL-C level at dose of 25 and 50 mg/kg. The Hesperidin and Apigenin had the antidiabetic activity with effects on lipids and other kidney markers..

The Role of Growth Differentiation Factor-15 in the Diagnosis of Patients with Chronic Angina Undergoing Coronary Angiography

Coronary artery disease (CAD) is considered the most prevalent leading cause of myocardial ischemia and mortality worldwide and can lead to angina pectoris and myocardial infarction (MI). Growth Differentiation Factor-15 (GDF-15) is usually measured together with other biomarkers to predict all-cause mortality. During stressful conditions associated with tissue injury and inflammation like myocardial ischemia, it is released into circulation and detected at high concentration in foam cells of the atherosclerotic plaque. Its circulating levels are associated with chronic diseases rather than acute diseases mainly cardiovascular diseases (CVDs) like CAD and chronic heart failure (CHF). The aim of the current study was to detect the role of GDF-15 as a new biomarker for the diagnosis of stable angina patients with normal left ventricular ejection fraction who were presented as having stable chest pain, so that to avoid endangering them to the invasive coronary angiography. Fasting venous blood samples were taken from 90 participants who were presented as having chest pain. They were all subjected to echocardiography, electrocardiography and coronary angiography. The left ventricular ejection fraction was calculated using the biplane M mode method. GDF-15 serum level was measured by using Human GDF-15 Sandwich ELISA Kit following the manufacturer’s instructions.The current study detected a high significant difference in the serum levels of GDF-15 and serum creatinine between the patients and the control group (P≤0.01). On the other hand, there were significant differences in the serum levels of triglycerides and VLDL-C between both study groups (P≤0.05). ROC curve analysis showed that GDF-15 had AUC= 1.00, the best cut off= 254.16 with sensitivity and specificity of 100%. So, it can be concluded that GDF-15 could be used as a biomarker for the diagnosis of stable angina patients with obstructive atherosclerotic plaque and normal LV ejection fraction.

Influence of Varied Dietary Cholesterol Levels on Lipid Metabolism in Hamsters.

Syrian hamsters are valuable models for studying lipid metabolism due to their sensitivity to dietary cholesterol, yet the precise impact of varying cholesterol levels has not been comprehensively assessed. This study examined the impact of varying dietary cholesterol levels on lipid metabolism in Syrian hamsters. Diets ranging from 0% to 1% cholesterol were administered to assess lipid profiles and oxidative stress markers. Key findings indicate specific cholesterol thresholds for inducing distinct lipid profiles: below 0.13% for normal lipids, 0.97% for elevated LDL-C, 0.43% for increased VLDL-C, and above 0.85% for heightened hepatic lipid accumulation. A cholesterol supplementation of 0.43% induced hypercholesterolemia without adverse liver effects or abnormal lipoprotein expression. Furthermore, cholesterol supplementation significantly increased liver weight, plasma total cholesterol, LDL-C, and VLDL-C levels while reducing the HDL-C/LDL-C ratio. Fecal cholesterol excretion increased, with stable bile acid levels. High cholesterol diets correlated with elevated plasma ALT activities, reduced hepatic lipid peroxidation, and altered leptin and CETP levels. These findings underscore Syrian hamsters as robust models for hyperlipidemia research, offering insights into experimental methodologies. The identified cholesterol thresholds facilitate precise lipid profile manipulation, enhancing the hamster's utility in lipid metabolism studies and potentially informing clinical approaches to managing lipid disorders.

Preptin as a Potential Marker in Iraqi Newly Diagnosed T2DM and T2DM with cardiovascular disease.

Objective: The aim of present work is to study the Role of preptin level in Iraqi type 2 diabetes patients and related with other biochemical parameters. Methods: This study was including (88) partespents, (22) newly diagnosed T2DM, (22) T2DM and (22) ischemic heart disease with T2DM, and (22) as healthy control, age ranged (35-63) years. Results: The findings indicate that individuals with type 2 diabetes mellitus (T2DM) exhibited markedly elevated levels of FBS, HbA1C, insulin, HOMA-IR, TC, TG, LDL-C, VLDL-C, and preptin in comparison to the control group. These differences were statistically significant (p<0.0001). Moreover, the Pearson correlation analysis revealed that preptin levels were positively associated with FBS, HbA1c, TC, TG, LDL, VLDL, insulin, and HOMA-IR while exhibiting a negative correlation with HDL. Conclusion: Because preptin plays a critical function in controlling sugar metabolism and, consequently, sugar problems, excessive levels of preptin play a significant role in the patient's inability to control both their level of glycosylated hemoglobin and their blood sugar levels. preptin levels are therefore high in diabetics and those with heart disease, which results in a loss of control over the body's metabolism and exposes a patient to many other ailments.

A cross talk study on sitagliptin mediated reclamation on TGF β signalling, DPP 4, miR-29a and miR-24 expression in PCOS rats fed with high fat-high fructose diet

Polycystic Ovary Syndrome (PCOS) is a multifactorial reproductive, endocrine and metabolic disturbance which is very commonly observed in females of reproductive age group. The disease is still incurable however the use of synthetic drugs in combination with lifestyle is recommended. Accordingly, the present study was conducted to investigate the possible beneficial effects of sitagliptin on PCOS induced rats on control diet (CD)/high fat- high fructose diet (HFFD). PCOS was induced by giving testosterone propionate (TP) for 28 days to both the CD/HFFD rats and treated with STG i.p. for last 15 days. At the end of the experiment lipid profile, inflammatory markers, expression of NF-κB-p65, miR-24 and miR-29a, fibrotic and apoptotic proteins from ovary tissue were examined. Moreover, lipid accumulation and fibrosis of ovary tissue was further confirmed using Sudan III and Masson’s trichrome stain. STG treated rats exerted a significant decrease in levels of cholesterol, TG, LDL-C, VLDL-C, IL-6 and TNF-α and increased HDL-C level, miR-24 and miR-29a expression. STG treated groups expressed significantly decreased expression of NF-κB-p65, TGF-β1, p-Smad 2 and p-Smad 3 followed by no significant changes in the expression of BAX, caspase-9, caspase-3 and Bcl-2 in all the PCOS induced groups. Among all the CD/ HFFD fed groups, rats on HFFD showed more devastating effect which suggests that diet plays a major role in genesis of PCOS. In conclusion, current results reflect the potential impact of STG against dyslipidaemia, inflammation and fibrosis in PCOS rats via regulating dyslipidaemia and fibrosis via DPP 4 mediated miR-29a expression.

PCSK9 plasma concentration is associated with epicardial adipose tissue volume and metabolic control in patients with type 1 diabetes

Patients with type 1 diabetes (T1D) have a greater risk of cardiovascular disease. Proconvertase subtilisin-kexin 9 (PCSK9) is involved in the atherosclerosis process. This study aimed to determine the relationship between PCSK9 levels and epicardial adipose tissue (EAT) volume and cardiometabolic variables in patients with T1D. This was an observational cross-sectional study including 73 patients with T1D. Clinical, biochemical and imaging data were collected. We divided the patients into two groups according to their glycemic control and the EAT index (iEAT) percentile. We performed a correlation analysis between the collected variables and PCSK9 levels; subsequently, we performed a multiple regression analysis with the significant parameters. The mean age was 47.6 ± 8.5 years, 58.9% were men, and the BMI was 26.9 ± 4.6 kg/m2. A total of 31.5%, 49.3% and 34.2% of patients had hypertension, dyslipidemia and smoking habit, respectively. The PCSK9 concentration was 0.37 ± 0.12 mg/L, which was greater in patients with worse glycemic control (HbA1c > 7.5%), dyslipidemia and high EAT volume (iEAT > 75th percentile). The PCSK9 concentration was positively correlated with age (r = 0.259; p = 0.027), HbA1c (r = 0.300; p = 0.011), insulin dose (r = 0.275; p = 0.020), VLDL-C level (r = 0.331; p = 0.004), TG level (r = 0.328; p = 0.005), and iEAT (r = 0.438; p < 0.001). Multiple regression analysis revealed that 25% of the PCSK9 variability was explained by iEAT and HbA1c (p < 0.05). The PCSK9 concentration is associated with metabolic syndrome parameters, poor glycemic control and increased EAT volume in patients with T1D.

Antidiabetic effect of the mixture of Cissus polyantha and Rytigynia senegalensis in high-fat diet and streptozocin-induced diabetic rats

BackgroundIn traditional Chinese medicine (TCM) practices, many plants of the Cissus and Rytigynia genera are used to treat many diseases including diabetes mellitus.The aim of this study was to evaluate the modulating effects of the mixture of the aqueous extracts of Cissus polyantha and Rytiginia senegalensis (CPRS) on some enzymes of carbohydrate metabolism, oxidative profile, and cardiovascular parameters in diabetic rats. MethodsDiabetes was induced by a diet enriched in high-fat for 30 days associated with a single intraperitoneal injection of streptozocin (35 mg/kg). Rats with a blood glucose level greater than or equal to 200 mg/dL were selected and divided into groups. Groups 1 and 2 received distilled water. Group 3 received metformin (40 mg/kg). Groups 4 and 5 received CPRS at doses of 50 and 111 mg/kg, respectively. Glycaemia, body mass, food and water intake, insulinemia, insulin resistance and insulin secretion indices, lipid profile and cardiovascular risk indices, oxidant profile, glycogen and liver enzymes were evaluated. Histology of the pancreas and heart was performed. ResultsCPRS (50 and/or 111 mg/kg) significantly (p < 0.05 to p < 0.001) reduced water and food consumption, blood glucose, HOMA-IR, coronary risk index, cholesterol, triglyceride, LDL-c, VLDL-c, and malondialdehyde levels, as well as glucose-6-phosphatase and fructose-1,6-biphosphatase activities in diabetic animals. In contrast, CPRS (50 and/or 111 mg/kg) caused an increase (p < 0.05 to p < 0.001) in body mass, insulinemia and HDL-c levels, reduced glutathione and hepatic glycogen. HOMA-β, insulin distribution, atherogenic and cardioprotective indices as well as superoxide dismutase, catalase, glucokinase, and glucose-6-phosphate dehydrogenase activities were also increased after CPRS administration. CPRS regenerated pancreatic islet β cells and decreased leukocyte infiltration in cardiomyocytes of diseased animals. ConclusionCPRS has hypoglycemic, antidyslipidemic, and antioxidant effects, thus validating its use in traditional medicine in the treatment of diabetes mellitus and its complications.

Impact of Heartfulness Meditation on Improving Antioxidant Status and Lipid Profile in Patients with Coronary Artery Disease

Introduction Oxidative stress plays an indispensable role in the pathogenesis of coronary artery disease (CAD). Several studies suggest that meditation can reduce oxidative stress and improve antioxidant status. This study was designed to evaluate the impact of heartfulness meditation on antioxidant status and lipid profile in patients with coronary artery disease. Methods Fifty-nine angiographically diagnosed CAD patients were included in the study. Patients who were enrolled practiced heartfulness meditation for a period of six months. Protein thiol (an antioxidant marker), serum total cholesterol (TC), triglycerides (TG), high-density lipoproteins (HDL-C), low-density lipoproteins (LDL-C), and very low-density lipoproteins (VLDL-C) were measured under fasting conditions before and after six months of meditation practice. Results After six months of practice of heartfulness meditation, there was a statistically significant increase in HDL-C (39.10 ± 8.30 vs. 42.85 ± 8.16, p &lt; .01) and an antioxidant marker protein thiol (257.34 ± 39.68 vs. 345.31 ± 57.53, p &lt; .0001). The mean levels of triglycerides (205.81 ± 88.31 vs. 182.53 ± 93.57 mg dl−1), VLDL-C (41.18 ± 17.64 vs. 36.51 ± 18.71 mg dl−1), and total cholesterol (170.02 ± 40.10 vs. 164.46 ± 42.20 mg dl−1) decreased following the intervention, although the differences were not statistically significant. Conclusion Heartfulness meditation is an effective means to decrease free radical formation and improve antioxidant status and lipid profile in CAD patients. As a result of this study, regular meditation practice has the potential to be one of the most effective non-pharmacological strategies for CAD prevention.

The Nephroprotective Potential of Brassica nigra Sprout Hydroalcoholic Extract against Carbon Tetrachloride-Induced Renal Toxicity in Rats.

The nephroprotective potential of the Brassica nigra sprout (BNS) hydroalcoholic extract against carbon tetrachloride (CCl4)-induced renal toxicity in rats was the object of this study. B. nigra sprouts were prepared in the lab to monitor the bio-changes in bioactive compounds during the sprouting for up to 7 days at 17 ± 1 °C and 90% relative humidity. Subsequently, 6-day sprouts of B. nigra were selected according to their phenolics and antioxidant activity, extracted, and examined for their nephroprotective and antioxidative stress potential at 250 and 500 mg sprout extracts kg-1 bw, in vivo. Weight gain, organ weight, lipid profile, atherogenic index, kidney functions, and oxidative stress biomarkers were assessed. The results indicated that the most proficient treatment for weight gain improvement was BNS extract at 500 mg kg-1. BNS at 250 mg kg-1 was remarked as the lowest weight gain enhancer compared to the NR group. A significant increase in TG, TC, LDL-c, and VLDL-c levels in the rats with CCl4-induced renal toxicity, and a significant decrease in HDL level, was noted. The administration of the BNS extract at 250 and 500 mg kg-1 considerably attenuated TG, TC, LDL-c, and VLDL-c levels, compared to the NR group. The most efficient treatment for improving the lipid profile was the BNS extract at 500 mg kg-1, even better than 250 mg kg-1. Administrating the BNS extract substantially attenuated the alterations in the creatinine, urea, and BUN caused by the CCl4 injection. The most efficient improvement was markedly recorded with the BNS extract at 500 mg kg-1, compared to the NR group. The rats treated with the BNS extract showed significant enhancement in GSH, CAT, and SOD activities and a considerable reduction in MDA levels. Administering the BNS extract at 250 and 500 mg kg-1 can efficiently reverse CCl4 inhibition of antioxidant enzyme activities, significantly increase GSH, CAT, and SOD, and decrease the MDA levels dose-dependently. The BNS extract at 250 and 500 mg kg-1 exhibits nephroprotection and antioxidative stress in a dose-dependent matter. The total nephroprotection % was recorded at 65.18% and 99.21% for rats treated with 250 and 500 mg kg-1, respectively. These findings could prove and potentiate the nephroprotective activities of the BNS extract in the range of the given doses. Further clinical studies are highly recommended for confirming the nephroprotection efficiency of the B. nigra sprout.

Effects of Seed of Different Mango Cultivars in Triton X-100 Induced Hyperlipdemic Rats

Hyperlipidemia is the most prevalent indicator for susceptibility to atherosclerotic heart diseases. The present study investigated the hypolipidemic potential of Mangifera haden, Mangifera pirie and combined extracts of Mangifera haden and Mangifera pirie seeds in Triton X-100 induced hyperlipidemic rats. Before the starting of the experiment, the animals were acclimatized to the laboratory conditions for a period of seven days. At the end of the acclimatization period, each rat was weighed and randomly divided into twelve groups of five animals each, comprising of test animals and control groups. Proximate analysis, toxicity studies, lipid profile parameters were determined in the study. The research study took place in the animal house of Biochemistry Department, University of Nigeria, Nsukka from July 2020 to August 2022. Proximate composition of Mangifera haden and Mangifera pirie seed extracts revealed that the (%) values of protein, lipid, crude fibre, ash, moisture, and carbohydrate are (4.82, 17.18, 4.29, 2.77, 8.39, 62.55) and (3.81, 20.20, 3.0, 1.0, 34.0, 37.99) respectively. Mangifera haden and Mangifera pirie were administered at different doses (200 mg, 300 mg, 500 mg) of the extracts per kilogram body weight of the animals while combined extract of Mangifera haden and Mangifera pirie were administered at 300 mg and 500 mg of the extract per kilogram body weight of the animals in Triton –Induced hyperlipidemic rats. Simvastatin and Atorvastatin were used as reference standards. Simvastatin was found to be an effective drug to Atorvastatin in lowering lipid profiles. The statistical analyses were carried out using one way ANOVA followed by Dunnett’s Post Hoc Multiple Comparisons test. Mangifera haden, Mangifera pirie and combined extracts of both species show significant decrease (P = 0.05) in the levels of serum Total Cholesterol, triacylglycerols, VLDL-C, LDL-C, Atherogenic index (A.I) and significant increase (P = 0.05) of serum HDL-C against Triton-Induced hyperlipidemic rats. The result also suggest that at 200 mg/kg Mangifera pirie and 300 mg/kg Mangifera haden body weight concentrations are an excellent lipid lowering agent. Single administration of either Mangifera haden or Mangifera pirie effectively suppressed the Triton-Induced hyperlipidemia in rats than the combined extracts. The organic extracts (Mangifera haden or Mangifera pirie) exhibited quite hypolipidemic potential when compared with one of the reference drugs, Atorvastatin which indicates that the organic extracts could be explored as an alternative therapeutic agent in the treatment of hyperlipidemia.

Syzygium cumini ameliorates high fat diet induced glucose intolerance, insulin resistance, weight gain, hepatic injury and nephrotoxicity through modulation of PTP1B and PPARγ signaling.

Metabolic disorders are majorly associated with insulin resistance and an impaired glucose tolerance. Since, many of the currently available drugs exhibit adverse effects and are resistant to therapies, natural products are a promising alternate in the alleviation of complex metabolic disorders. In the current study, Syzygium cumini methanolic extract (SCE) was investigated for its anti-diabetic and anti-adipogenic potential using C57BL/6 mice fed on high fat diet (HFD). The HFD fed obese mice were treated with 200 mg/kg SCE and compared with positive controls Metformin, Pioglitazone and Sodium Orthovanadate. The biometabolites in SCE were characterized using Fourier transform infrared and gas chromatography and mass spectroscopy. A reduction in blood glucose levels with improved insulin sensitivity and glucose tolerance was observed in SCE-treated HFD obese mice. Histopathological and biochemical investigations showed a reduction in hepatic injury and nephrotoxicity in SCE-administered HFD mice. Results showed inhibition of PTP1B and an upregulation of IRS1 and PKB-mediated signaling in skeletal muscle. A significant decrease in lipid markers such as TC, TG, LDL-c and VLDL-c levels were observed with increased HDL-c in SCE-treated HFD mice. A significant decrease in weight and adiposity was observed in SCE-administered HFD mice in comparison to controls. This decrease could be due to the partial agonism of PPARγ and an increased expression of adiponectin, an insulin sensitizer. Hence, the dual-modulatory effect of SCE, partly due to the presence of 26% Pyrogallol, could be useful in the management of diabetes and its associated maladies.

Relationship between Lipid Profile and Thyroid Disturbance and Ischemic Heart Disease in Iraqi Patients

The current study is a case-control study conducted in Baghdad city between 1st of January to the end of, 2023. The study focused on patients admitted to the Coronary Care Unit of Ibn Al Nafees Hospital and Ibn Al Bitar Hospital in Baghdad. And Alyarmok Hospital in Baghdad. The study included 60 Iraqi patients with coronary heart disease, ranging in age from 37 to 66 years. A control group of 30 apparently healthy individuals (15 men and 15 women) was included in the study. The control group was matched with the patients in terms of gender and age to improve the accuracy of the results. Blood samples were collected from both patients and control individuals after 12 hours of fasting. Biochemical colorimetric methods by spectrophotometer were used to determine total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL), and Immunofluorescence technique by Afias was used to determine triiodothyronine (T3), thyroxine (T4), and TSH levels and HbA1C levels in the blood. The study analyzed the demographic characteristics of patients with ischemic heart disease (IHD) and the control group, including age groups, sex distribution, and BMI. The majority of IHD patients were non-smokers, with 26.67% being smokers and the majority being non-smokers. The majority of IHD patients had hypertension, while 58.33% had diabetes. The cholesterol levels in IHD patients were significantly higher than the control group, with a p-value of 0.001. The triglyceride levels were also significantly elevated in IHD patients, with a p-value of 0.001. LDL-c levels were significantly elevated in IHD patients, while very low-density lipoprotein cholesterol (VLDLc) levels were significantly elevated in IHD patients. IHD patients had significantly higher T3 levels (1.701 ± 1.21) than the control group (0.87 ± 0.16), suggesting potential differences. T4 levels were also significantly higher in IHD patients with thyroid dysfunction (106.7 ±86.5) compared to the control group (78.5 ±13.65). On the other hand, TSH levels did not show a significant difference between IHD patients with thyroid dysfunction (3.29 ± 2.55) and the control group (3.18 ±2.078). The study found no significant differences in thyroid function parameters among the different age groups of individuals with hypothyroidism. The mean T3 level in the 40-49 age group was 0.49±0.02, the mean T4 level was 43.5±0.7, and the mean TSH level was 4.88±0.38. For the 50-59 age group, the mean T3 level was 0.36±0.17, the mean T4 level was 44.6±0.54, and the mean TSH level was 5.41±1.07. In the &gt;59 age group, the mean T3 level was 0.51±0.03, the mean T4 level was 45.8±6.9, and the mean TSH level was 5.24±0.66. The study showed that hypothyroidism IHD patients tend to be associated with higher levels of cholesterol, triglycerides, LDL-c, and VLDL-c. The highest prevalence of hyperthyroidism among individuals with hypertension was 72.73%, while the highest spread was seen in hypothyroidism among individuals with diabetes. The highest mean value for HbA1c was observed in patients with hypothyroidism (6.99±0.82%), followed by patients with hyperthyroidism (6.46±0.51), and the lowest mean value was seen in patients with normal thyroid function (4.36±0.56%). These differences in mean HbA1c levels among the three groups are statistically significant, as indicated by the p-value: of 0.017.

Osteopontin (SPP1) expression on gallstone formation in rabbits fed with a lithogenic diet.

This research was designed to assess the influence of the administration of a lithogenic diet, hydrogen peroxide, and vitamin AD3E on rabbits' gallstone formation and to envisage the expression of osteopontin (OPN) in their hepatic tissues. Twenty-four healthy local mature rabbits of both genders were divided into four equal groups. At the end of the feeding period, samples of blood were taken from all rabbits after they had fasted overnight to estimate the serum lipid profile. And some of the hepatic tissue has been preserved at -28°C for molecular analysis and gene expression. The gallstones were formed 100% in the GIII and 50% in the GIV. The mRNA OPN expression showed a significant increase in the GIII when compared with other groups. In Groups III and II, the serum levels of total cholesterol, Triglyceride, L-C, low-density lipoprotein-choles, and VLDL-C were significantly increased when compared with GI, while in GIII, the serum level of high-density lipoprotein-cholesterol was significantly decreased when compared with GI. It was concluded that the expression of the mRNA OPN was increased in the hepatic tissue of gallstone-formed rabbits.

Role of paraoxonase 1 activity and PON1 gene polymorphisms in sickle cell disease

Sickle cell disease (SCD) patients often exhibit a dyslipidemic sub-phenotype. Paraoxonase 1 (PON 1) is a serum glycoprotein associated with the high-density lipoproteins cholesterol (HDL-C), and variability in PON1 activity depends on the PON1 genotypes. We investigated the influence of PON1c.192Q > R and PON1c.55L > M polymorphisms on PON1 activity and laboratory parameters and the association between PON1 activity and clinical manifestations in SCD patients. We recruited 350 individuals, including 154 SCD patients and 196 healthy volunteers, which comprised the control group. Laboratory parameters and molecular analyses were investigated from the participants' blood samples. We have found increased PON1 activity in SCD individuals compared to the control group. In addition, carriers of the variant genotype of each polymorphism presented lower PON1 activity. SCD individuals carrying the variant genotype of PON1c.55L > M polymorphism had lower platelet and reticulocyte counts, C-reactive protein, and aspartate aminotransferase levels; in addition to higher creatinine levels. SCD individuals carrying the variant genotype of PON1c.192Q > R polymorphism had lower triglyceride, VLDL-c, and indirect bilirubin levels. Furthermore, we observed an association between PON1 activity history of stroke and splenectomy. The present study confirmed the association between PON1c.192Q > R and PON1c.55L > M polymorphisms and PON1 activity, in addition to demonstrate their effects on markers of dislipidemia, hemolysis and inflammation, in SCD individuals. Moreover, data suggest PON1 activity as a potential biomarker related to stroke and splenectomy.

Combined oral contraceptives and their impact on lipids, blood pressure, and body mass index in pregnant women

Objective: To determine how combination oral contraceptive pills (COCPs) affect women of reproductive age's lipid profiles, blood pressure, and body mass index. Methodology: This cross-sectional study looked at the family planning programmes at the tertiary referral hospitals in Peshawar. We looked at married, childbearing women (aged 14 to 49). Group 1 (those who had used COCPs for at least six months) and Group 2 (controls of a comparable age who had not used COCPs) were created. Fasting blood TC, TG, HDL-C, LDL-C, and VLDL-C levels were assessed using a chemical analyser. Hb and platelet levels were assessed by a haematology analyst. Everyone had their BMI and blood pressure measured. The parameters of the oral and control groups were compared using SPSS. Results: The average BMI of Group 1 (Oral COCP) was 28.12 kg/m2 (+/- 0.50 SEM), while the average BMI of Group 2 (Control) was 26.25 kg/m2 (+/- 0.43 SEM). The mean BMIs of the two groups were very different (p-value: 0.0003). Women in Group 1 who took combined oral contraceptives had a much higher BMI than women in Group 2 who did not. BMI is used to measure health. It is based on height and weight.

Serum bilirubin levels are negatively associated with atherogenic lipids in Saudi subjects with type 2 diabetes: A pilot study

&lt;b&gt;Background: &lt;/b&gt;Recent research has demonstrated the possible relevance of bilirubin in metabolic and cardiovascular disorders. Lipid abnormalities are a major problem that is related with an increased risk of cardiovascular disease in diabetics. This study examined the relationship between serum bilirubin and direct bilirubin concentrations and atherogenic lipids in patients with type 2 diabetes (T2DM).&lt;br /&gt; &lt;b&gt;Methods&lt;/b&gt;: This cross-sectional included 67 patients with type 2 diabetes and 39 matched healthy control. The lipid profile, including total cholesterol, HDL-C, and TG levels, fasting blood glucose, total bilirubin, direct bilirubin, ALT, AST, and ALP were measured using a dimension EXL clinical chemistry analyzer (Siemens Healthcare Diagnostics). Cholesterol in VLDL, LDL, and sdLDL were calculated from standard lipid assay results by the equations of Sampson et al.&lt;br /&gt; &lt;b&gt;Results&lt;/b&gt;: Serum bilirubin was lower in non T2DM subjects nearly significant (p=0.0.51) whereas direct bilirubin concentrations were lower in T2DM (p=0.008). ALT, AST, and ALP levels were higher in T2DM groups. The mean values of LDL-C, sdLDL-C, non HDL-C and VLDL-C were significantly increased in T2DM group and lower HDL-C. An inverse relationship could be observed with increase in serum total bilirubin and serum levels of LDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.139, p&amp;lt;0.005), sdLDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.137, p&amp;lt;0.005), VLDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.074, p&amp;lt;0.044), and non HDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.166, p&amp;lt;0.002) in T2DM group. The same inverse relationship was observed with serum direct bilirubin and serum levels of LDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.133, p&amp;lt;0.006), sdLDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.172, p&amp;lt;0.001), VLDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.118, p&amp;lt;0.01), and non HDL-C (r&lt;sup&gt;2&lt;/sup&gt;=0.182, p&amp;lt;0.001) in T2DM group.&lt;br /&gt; &lt;b&gt;Conclusions&lt;/b&gt;: A significant negative association was found between serum bilirubin levels and direct serum bilirubin with atherogenic lipids, suggesting that serum bilirubin may protect T2DM patients from development of cardiovascular disease. These findings indicate the need for additional research in a large cohort.

Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions.

Fennel seeds and flaxseed have been traditionally used against many medical ailments due to their medicinal characteristics. The aim of the study was to investigate the health properties of secoisolariciresinol diglucoside (SDG) and anethole from flaxseed and fennel seeds in rats fed with high-fat diet. Histopathological changes in the heart and liver were also examined. Sixty rats were divided into two main groups. Group I (10 rats) was used as a negative control group and fed on the basal diet only. Group II (50 rats) was fed a hypercholesterolemic diet but not given any drugs during the trial for 2 weeks. This group was further divided into five subgroups (10 rats each). One of them was fed on the basal diet and used as a positive control group. However, the other four subgroups were fed on basal diets and anethole (20 mg/kg/day, orally), SDG (20 mg/kg/day, orally), a mixture of anethole + SDG (10 + 10 mg/kg/day, orally), and atorvastatin (10 mg/kg/day, orally) for 6 weeks. Compared to control, treatment with a combination of anethole + SDG showed a significant (p ≤ .05) improvement in serum levels of triglyceride (TG) (137.88 ± 1.61 mg/dL), total cholesterol-(TC) (180.12 ± 8.99 mg/dL), LDL-C (46.40 ± 6.67 mg/dL), VLDL-C (11.81 ± 1.07 mg/dL), aspartate aminotransferase (AST) (75.97 ± 6.92 U/L), alanine aminotransferase (ALT) (34.83 ± 2.17 U/L), alkaline phosphatase (ALP) (130.65 ± 1.05 U/L), and malondialdehyde (MDA) (30.12 ± 1.89 mmol/g), and improved activities of catalase (70.99 ± 3.29 U/g) and superoxide dismutase (SOD) (35.13 ± 2.53 U/dL) enzymes while SDG and anethole group had relatively less impact. Atorvastatin also improved serum levels of triglyceride, total cholesterol, LDL-C, and VLDL-C significantly and rose serum high-density lipoprotein cholesterol (HDL-C) levels considerably meanwhile it had a minor but negative impact on AST, ALT, and ALP, and negligible impact on activities of MDA, CAT, and SOD enzymes compared to the positive control group. The study revealed that combining anethole and SDG may improve dyslipidemia, improve lipid profile, decrease risks of chronic heart diseases, increase HDL-C, and enhance antioxidant enzymes' activities.

Effect of Bay leaf (Laurus nobilis L.) and its isolated (flavonoids and glycosides) on the lipids profile in the local Iraqi female rabbits

The present study aimed to explain the effect of Bay leaf and its isolated flavonoids and glycosides on the levels of TC, TG, HDL-C, LDL-C and VLDL-C in the local Iraqi female rabbits. Isolation of flavonoids and glycosides from Bay leaf were carried out, the study design included four groups (n=6): Control group-C fed with standard pellet diet; group1-G1 orally administrated daily dose 100 mg/ml/kg of Bay leaf crude for 30 days; group2-G2 orally administrated daily dose 50 mg/ml/kg of isolated flavonoids for 30 days; group3-G3 orally administrated daily dose 12.5 mg/ml/kg of isolated glycosides for 30 days. TC, TG and HDL-C were determined by enzymatic colorimetric method. The results showed that oral administration of Bay leaf and its isolated flavonoids and glycosides reduced levels of TC, TG, LDL-C and VLDL-C compared to control, therefore Bay leaf useful agent in reducing hyperlipidemia.

CARNOSINE-LOADED ORAL NIOSOMES AMELIORATE HIGH-FRUCTOSE-INDUCED METABOLIC SYNDROME IN RATS VIA MODULATION OF SIRT1, A METABOLIC MASTER SWITCH

Metabolic syndrome is a crucial health challenge, and the available therapeutic agents are still not effective. Carnosine, a cytoplasmic dipeptide, is a potent anti-glycation, anti-oxidant, anti-inflammatory and chelating agent. However, whether carnosine would be assumed as a potential hypoglycemic agent or not, no decisive report with detailed mechanisms is found yet. As such, we suggest the carnosine-loaded in niosomes as a prospective solution to bypass its unwanted fast degradation by carnosinase which is considered as a major obstacle with the clinical application of carnosine as an oral drug therapy. Toward this, the purpose of our study is to assess the profits of oral administration of carnosine, and carnosine-loaded niosome in HFD-induced metabolic syndrome rats and to inspect some of the involved mechanisms. Initially, carnosine-loaded niosomes were prepared and characterized. Then, metabolic syndrome was provoked by 60% fructose diet in male Sprague Dawley rats where carnosine and carnosine-loaded niosomes were orally administered at doses 50 mg/kg and 25 mg/kg, respectively. In addition, biochemical and molecular studies were performed to clarify the possible mechanisms of action. Data showed that the consumption of 60% fructose diet displayed a tremendous increment in body weight, body mass index as well as a significant elevation in levels of serum glucose, insulin, TAG, TC, LDL-c, VLDL-c and FFA. Also, it showed a significant reduction in levels of serum HDL-c. Furthermore, HFD provoked up-regulation of SREBP-1c and FAS mRNA levels in adipose tissue. Also, it induced down-regulation of SIRT1, GLUT-4 mRNA levels in adipose tissue. We found that oral administration of either carnosine or carnosine-loaded niosome effectively reversed HFD-mediated alterations via SIRT1 activation. Overall, oral delivery of carnosine-loaded niosome had a better efficacy than oral carnosine, attenuating HFD-mediated alterations. Carnosine nano-formulation is a new excellent candidates for metabolic syndrome management and needs further exploration of its mechanisms.